Fan Huiqian, Wang Weijun, Yan Jingjing, Xiao Li, Yang Ling
Division of Gastroenterology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
Cancer Cell Int. 2018 Dec 19;18:212. doi: 10.1186/s12935-018-0702-0. eCollection 2018.
CXC chemokine receptor 7 (CXCR7) is frequently overexpressed in a variety of tumors. Nevertheless, whether CXCR7 can be used as a tumor prognosis marker has not been systematically assessed. The current meta-analysis was performed to obtain an accurate evaluation of the relationship between CXCR7 level and the prognosis of cancer patients.
Embase, Web of Science, and PubMed were systematically searched according to a defined search strategy up to June 11, 2018. Then, the required data were extracted from all qualified studies which were screened out based on the defined inclusion and exclusion criteria. Finally, the hazard ratios (HR) with 95% confidence intervals (CI) were used to evaluate the prognostic significance of CXCR7 in tumor patients.
A total of 28 original research studies comprising 33 cohorts and 5685 patients were included in this meta-analysis. The results showed that CXCR7 overexpression was significantly related to worse overall survival (OS) (HR 1.72; 95% CI 1.49-1.99), disease-free survival (DFS) (HR 5.58; 95% CI 3.16-9.85), progression-free survival (PFS) (HR 2.83; 95% CI 1.66-4.85) and recurrence-free survival (RFS) (HR 1.58; 95% CI 1.34-1.88) in cancer patients. Furthermore, for certain types of cancer, significant associations between higher CXCR7 expression and worse OS of glioma (HR 1.77; 95% CI 1.43-2.19), breast cancer (HR 1.45; 95% CI 1.28-1.63), esophageal cancer (HR 2.72; 95% CI 1.11-6.66) and pancreatic cancer (HR 1.46; 95% CI 1.12-1.90) were found. However, for lung cancer and hepatocellular cancer, there was no significant relationship between CXCR7 expression level and OS, (HR 2.40; 95% CI 0.34-17.07) and (HR 1.37; 95% CI 0.84-2.24) respectively.
Increased CXCR7 level could predict poor prognosis of tumor patients and might be regarded as a novel prognostic biomarker for tumor patients.
CXC趋化因子受体7（CXCR7）在多种肿瘤中常过度表达。然而，CXCR7是否可作为肿瘤预后标志物尚未得到系统评估。进行当前的荟萃分析以准确评估CXCR7水平与癌症患者预后之间的关系。
根据既定检索策略，对截至2018年6月11日的Embase、Web of Science和PubMed进行系统检索。然后，从所有符合条件的研究中提取所需数据，这些研究是根据既定的纳入和排除标准筛选出来的。最后，使用95%置信区间（CI）的风险比（HR）来评估CXCR7在肿瘤患者中的预后意义。
本荟萃分析共纳入28项原始研究，包括33个队列和5685例患者。结果显示，CXCR7过表达与癌症患者较差的总生存期（OS）（HR 1.72；95% CI 1.49 - 1.99）、无病生存期（DFS）（HR 5.58；95% CI 3.16 - 9.85）、无进展生存期（PFS）（HR 2.83；95% CI 1.66 - 4.85）和无复发生存期（RFS）（HR 1.58；95% CI 1.34 - 1.88）显著相关。此外，对于某些类型的癌症，CXCR7高表达与胶质瘤（HR 1.77；95% CI 1.43 - 2.19）、乳腺癌（HR 1.45；95% CI 1.28 - 1.63）、食管癌（HR 2.72；95% CI 1.11 - 6.66）和胰腺癌（HR 1.46；95% CI 1.12 - 1.90）较差的OS之间存在显著关联。然而，对于肺癌和肝细胞癌，CXCR7表达水平与OS之间分别无显著关系（HR分别为2.40；95% CI 0.34 - 17.07）和（HR 1.37；95% CI 0.84 - 2.24）。
CXCR7水平升高可预测肿瘤患者预后不良，可能被视为肿瘤患者的一种新型预后生物标志物。
Zotero 插件
